Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies

Novo Holdings United Kingdom United States of America Denmark

Investment addresses the need for disease-modifying therapies targeting the root causes of fibrosisFunding will support the advancement of CCN family inhibitor TRX-44 into clinical trials for treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF)Novo Holdings and HealthCap co-created Tribune in 2020or follow us on LinkedIn.

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

View original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-participates-in-23-million-series-a-for-tribune-therapeutics-to-advance-next-generation-anti-fibrotic-therapies-302411302.html

@ prnewswire.co.uk